Publications by authors named "Jeffrey L Probstfield"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,834,527

Total Likes

44,601

Extended Reach

3,299,708

Social Features

199
L
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis

N Engl J Med· December 2015

Videos about Article: user user

2 9 11 3 15

View All Article and Social Media Activity
E
Effects of intensive blood-pressure control in type 2 diabetes mellitus.

April 2010

Videos about Article: user user user

3 1 4 27 16 26

View All Article and Social Media Activity
E
Effects of intensive glucose lowering in type 2 diabetes.

N Engl J Med· June 2008

Videos about Article: user user user 17

20 10 135 26 29

View All Article and Social Media Activity
E
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston, Jeffrey L Probstfield

Chest· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic yield, safety, and outcomes of Head-to-pelvis sudden death CT imaging in post arrest care: The CT FIRST cohort study.
Kelley R H Branch, Medley O Gatewood, Peter J Kudenchuk, Charles Maynard, Michael R Sayre, Jeffrey L Probstfield

Resuscitation· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
Hertzel C Gerstein, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Jeffrey L Probstfield

Diabetes Obes Metab· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
Kelley R H Branch, Jeffrey L Probstfield, Jackie Bosch, Deepak L Bhatt, Aldo P Maggioni

Am Heart J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scoping review of echocardiographic parameters associated with diagnosis and prognosis after resuscitated sudden cardiac arrest.
Linda Liu, Aris Karatasakis, Peter J Kudenchuk, James N Kirkpatrick, Michael R Sayre, Jeffrey L Probstfield

Resuscitation· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
John W Eikelboom, Jacqueline Bosch, Stuart J Connolly, Jessica Tyrwitt, Keith A A Fox, Jeffrey L Probstfield

Eur Heart J Cardiovasc Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'.
Kelley R H Branch, Hertzel C Gerstein, Jeffrey L Probstfield

Eur J Heart Fail· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Kelley R H Branch, Gilles R Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, Jeffrey L Probstfield

Eur J Heart Fail· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study.
Hertzel C Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Kober, Jeffrey L Probstfield

Diabetes Care· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.
Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Jeffrey L Probstfield

J Am Heart Assoc· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects.
Graziella E Ronsein, Tomas Vaisar, W Sean Davidson, Karin E Bornfeldt, Jeffrey L Probstfield

Arterioscler Thromb Vasc Biol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
Gilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, Darryl P Leong, Victor Aboyans, Jeffrey L Probstfield

Heart· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early head-to-pelvis computed tomography in out-of-hospital circulatory arrest without obvious etiology.
Kelley R H Branch, Jared Strote, Martin Gunn, Charles Maynard, Peter J Kudenchuk, Jeffrey L Probstfield

Acad Emerg Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Gilles R Dagenais, Lars Rydén, Lawrence A Leiter, Mark Lakshmanan, Leanne Dyal, Jeffrey L Probstfield

Cardiovasc Diabetol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Mukul Sharma, Robert G Hart, Eric E Smith, Jacqueline Bosch, John W Eikelboom, Jeffrey L Probstfield

Stroke· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic accuracy of early computed tomographic coronary angiography to detect coronary artery disease after out-of-hospital circulatory arrest.
Kelley R Branch, Ravi Hira, Robin Brusen, Charles Maynard, Peter J Kudenchuk, Jeffrey L Probstfield

Resuscitation· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome.
Sung-Hee Shin, Brian Claggett, Marc A Pfeffer, Hicham Skali, Jiankang Liu, Jeffrey L Probstfield

Eur J Heart Fail· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
William E Boden, Michael G Miller, Ruth McBride, Christopher Harvey, Michael C Snabes, Jeffrey L Probstfield

Am Heart J· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI).
Kevin R Bainey, Robert C Welsh, Stuart J Connolly, Tamara Marsden, Jackie Bosch, Jeffrey L Probstfield

Circulation· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
Jeffrey L Probstfield, William E Boden, Todd Anderson, Kelley Branch, Moti Kashyap

J Clin Lipidol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Kelley R Branch, Jeffrey L Probstfield, John W Eikelboom, Jackie Bosch, Aldo P Maggioni

Circulation· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Mukul Sharma, Robert G Hart, Eric E Smith, Jackie Bosch, Fei Yuan, Jeffrey L Probstfield

Int J Stroke· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.
Jelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, Rafael Diaz, Hertzel C Gerstein, Jeffrey L Probstfield

J Diabetes Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
L Julian Haywood, Barry R Davis, Linda B Piller, Lara M Simpson, Alokananda Ghosh, Jeffrey L Probstfield

J Natl Med Assoc· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Jeffrey L Probstfield

Circulation· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis